AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03619837
Drug: Sofosbuvir/Velpatasvir
RxNorm normalized name: SOFOSBUVIR/VELPATASVIR
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
Trial: NCT02744508
Drug: palonosetron
RxNorm normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02744508
Drug: palonosetron with dexamethasone
DrugBank: Palonosetron (DB00377)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01839253
Drug: b-blocker(Atenolol)
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03619837
Drug: Sofosbuvir/Velpatasvir/Voxilaprevir
RxNorm normalized name: sofosbuvir/velpatasvir/voxilaprevir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks.
Trial: NCT01769482
Drug: Udenafil
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
Trial: NCT03432572
Drug: Pyridium
RxNorm normalized name: Pyridium
DrugBank: Phenazopyridine (DB01438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a urine discoloration agent
Trial: NCT03432572
Drug: Riboflavin
RxNorm normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a urine discoloration agent
Trial: NCT00288236
Drug: Rimonabant (SR141716)
RxNorm normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT02127918
Drug: ESES treated with clobazam
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
Trial: NCT01453530
Drug: Sugammadex
RxNorm normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single dose of sugammadex 2 mg/kg iv
Trial: NCT01453530
Drug: Neostigmine/Glycopyrrolate
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
Trial: NCT04824131
Drug: Oral cabotegravir (CAB)
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg tablets
Trial: NCT04824131
Drug: CAB LA
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
Trial: NCT00504010
Drug: Arnica Montana
RxNorm normalized name: Arnica montana
DrugBank: Arnica montana (DB14297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied to lower extremity once a day for 3 days
Trial: NCT00807014
Drug: Duac Gel
RxNorm normalized name: benzoyl peroxide / clindamycin phosphate Topical Gel [Duac]
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duac® Gel will be applied to the face once daily at night, for 12 weeks.
Trial: NCT00021242
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous IV infusion
Trial: NCT04824131
Drug: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300 mg/200 mg fixed-dose combination tablets
Trial: NCT00807014
Drug: Differin gel
RxNorm normalized name: adapalene Topical Gel [Differin]
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Differin Gel will be applied to the face once daily at night, for 12 weeks.
Trial: NCT02035124
Drug: Cabazitaxel
RxNorm normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02105350
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02105350
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03480971
Drug: Tempol
RxNorm normalized name: Tempol
DrugBank: Tempol (DB12449)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
Trial: NCT00769418
Drug: odanacatib
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days.
Trial: NCT03168438
Drug: Letetresgene autoleucel
RxNorm normalized name: Letetresgene autoleucel
DrugBank: Letetresgene autoleucel (DB17233)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion
Trial: NCT03168438
Drug: Letetresgene autoleucel with pembrolizumab
RxNorm normalized name: Letetresgene autoleucel
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
Trial: NCT03168438
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
Trial: NCT03168438
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is available as an IV infusion
Trial: NCT00642161
Drug: budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02707328
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02707328
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01289171
Drug: Glycolic acid
RxNorm normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
Trial: NCT02321761
Drug: Amantadine hydrochloride
RxNorm normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
Trial: NCT03124082
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
Trial: NCT03124082
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
Trial: NCT03124082
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clonidine 4 mcg/kg
Trial: NCT01455233
Drug: besivance
RxNorm normalized name: Besivance
DrugBank: Besifloxacin (DB06771)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
Trial: NCT01037543
Drug: HM10460A or placebo or Neulasta
RxNorm normalized name: edaravone
DrugBank: Edaravone (DB12243)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
Trial: NCT02338609
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: At the discretion of the investigator, pediatric patients could be treated with commercially available everolimus, as per local product information / standard of care. Treatment duration and dose modifications were at the investigator's discretion, as per the local product information.
Trial: NCT04530344
Drug: ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
Trial: NCT05297123
Drug: All-trans retinoic acid
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) 20mg 3 times a day for 8 weeks.
Trial: NCT05297123
Drug: Arsenic Trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ATO 0.15mg/kg/d for 8 weeks (If the total daily amount is greater than 10mg, only 10mg/d can be given)
Trial: NCT05297123
Drug: Realgar-Indigo naturalis formula
RxNorm normalized name: indigo
DrugBank: Indigo (DB16862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg/kg/d for 8 weeks
Trial: NCT01455233
Drug: vigamox
RxNorm normalized name: Vigamox
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
Trial: NCT02977156
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
Trial: NCT00026208
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8
Trial: NCT00026208
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy
Trial: NCT00026208
Drug: Bleomycin
RxNorm normalized name: Bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 u/m² intravenously (IV) on week 2, 4, 6, 8
Trial: NCT00026208
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)
Trial: NCT00014313
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00014313
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00546507
Drug: TDS-943 (topical diclofenac sodium 4% spray)
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02805855
Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells
RxNorm normalized name: Allogeneic bone marrow-derived mesenchymal stromal cells
DrugBank: Autologous adipose derived mesenchymal stromal cells (DB17925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
Trial: NCT00139919
Drug: Bifeprunox
RxNorm normalized name: Bifeprunox
DrugBank: Bifeprunox (DB04888)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03428373
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban 10mg daily
Trial: NCT03428373
Drug: ASA
RxNorm normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ASA 81mg
Trial: NCT05100563
Drug: 50 mg naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication combined with twice a week psychotherapy
Trial: NCT01723774
Drug: Anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01723774
Drug: Goserelin
RxNorm normalized name: Goserelin
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02939183
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone
Trial: NCT02939183
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide
Trial: NCT01240200
Drug: Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
Trial: NCT04769297
Drug: Sublingual Micro-Dose Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily micro-dosing of frontline healthcare workers suffering from acute stress disorder due to the COVID-19 pandemic
Trial: NCT03416179
Drug: glasdegib
RxNorm normalized name: Glasdegib
DrugBank: Glasdegib (DB11978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily Glasdegib (100 mg, PO), beginning on Day 1 and is to continue up to 2 years post randomization.~Following consolidation therapy, glasdegib or placebo will be administered daily for up to 2 years after randomization or until they have minimal residual disease (MRD) negative disease, whichever comes first.~Daily Glasdegib (100 mg, PO) or matching placebo will continue throughout Induction(s) and Consolidation therapies regardless of dose modifications/delays in the chemotherapy.
Trial: NCT01331109
Drug: Milnacipran
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
Trial: NCT03416179
Drug: daunorubicin + cytarabine
RxNorm normalized name: DAUNORUBICIN/CYTARABINE
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: '7+3' (cytarabine 100 mg/m2, IV for 7 days by continuous infusion and daunorubicin 60 mg/m2 for 3 days).~If a second induction is needed, Investigators may choose either a 5 day cytarabine continuous infusion plus daunorubicin for 2 days ('5+2') or a 7 day cytarabine continuous infusion plus daunorubicin for 3 days ('7+3');
Trial: NCT03416179
Drug: azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (75 mg/m2, SC or IV) daily for 7 days, in 28 day cycles for as long as they do not meet the criteria for disease progression, unacceptable toxicity, consent withdrawal, or death.
Trial: NCT00230958
Drug: Viramidine
RxNorm normalized name: Viramidine
DrugBank: Taribavirin (DB06408)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230958
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00230958
Drug: pegylated interferon alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00663403
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomcyin 8 mg/kg infused intravenously every 48 hours
Trial: NCT03416179
Drug: glasdegib
RxNorm normalized name: Glasdegib
DrugBank: Glasdegib (DB11978)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glasdegib 100 mg PO QD is to be administered by mouth daily beginning on Day 1 of chemotherapy and will continue if subjects demonstrate reasonable evidence of clinical benefit and do not meet the criteria for progression regardless of any delays/modifications in the chemotherapy treatment.~Subjects will continue glasdegib until disease progression, unacceptable toxicity, consent withdrawal, or death, whichever comes first.
Trial: NCT03416179
Drug: cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Consolidation with single agent cytarabine 3 g/m2 IV for adults \<60 years and 1 g/m2 for adults 60 years over 3 BID on Days 1, 3, and 5, every 28 days for up to 4 cycles or alternative single agent cytarabine consolidation schedules may be used per local prescribing information.
Trial: NCT01711125
Drug: Baclofen 30mg/day
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30mg/day 10 mg t.i.d
Trial: NCT01711125
Drug: Baclofen 75mg/day
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/day 25 mg t.i.d
Trial: NCT04398459
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Each recruited subject will accept Ibrutinib treatment.
Trial: NCT00202397
Drug: Riluzole
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: capsule-shaped 50 mg tablets bid for 8 weeks
Trial: NCT03776279
Drug: Mitoxantrone Hydrochloride Liposome Injection
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitoxantrone Hydrochloride Liposome Injection 20 mg/m2 will be infused intravenously once over 60min in 250 ml 5％ glucose injection on the first day during a treatment phase of 4 weeks.
Trial: NCT01465815
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01465815
Drug: linsitinib
RxNorm normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01537250
Drug: Levofloxacin 500 mg placebol
RxNorm normalized name: levofloxacin 500 MG
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral form,,once adily,7\~10 days
Trial: NCT01537250
Drug: Nemonoxacin 3 tablets
RxNorm normalized name: nemonoxacin
DrugBank: Nemonoxacin (DB06600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral form,once daily,7\~10 days
Trial: NCT01538446
Drug: Modification of Prasugrel based on a biological assay
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
Trial: NCT01538446
Drug: prasugrel / clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: fixed dose of prasugrel 5 mg
Trial: NCT00318656
Drug: rosiglitazone-metformin fixed dose combination
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00318656
Drug: metformin + glimepiride
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03199690
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Antiviral (integrase inhibitor)
Trial: NCT03199690
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic
Trial: NCT03356015
Drug: 4L Polyethylene Glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4L group received double-dose PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes.
Trial: NCT03356015
Drug: 3L Polyethylene Glycol
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3L group were instructed to drink 1L PEG at 19:00 in the evening before the day of colonoscopy at a rate of 250 mL every 15 minutes
Trial: NCT02911272
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
Trial: NCT00025467
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT01658410
Drug: BQ-123
RxNorm normalized name: BQ-123
DrugBank: BQ-123 (DB12054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
Trial: NCT01658410
Drug: NaCl
RxNorm normalized name: NaCl
DrugBank: Linaclotide (DB08890)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: NaCl, Route: intracoronary
Trial: NCT02305979
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02682121
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 850 mg twice daily